埃沃洛库马布使用与大动脉狭窄症缓慢进展之间的关联
Kengo Terasaka1,2, Masaomi Gohbara3, Takeru Abe2
1Division of Cardiology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, 232-0024, Japan.
Heart and vessels
|March 19, 2024
概括
在中度病例中,Evolocumab可能会减缓主动脉狭窄症 (AS) 的进展. 这项研究发现,与标准护理相比,evolocumab的使用与AS进展的减缓和不良事件的减少有关.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 大动脉狭窄 (AS) 是一种渐进的疾病,目前没有药物治疗来抑制其进展.
- 了解潜在的治疗剂对于管理AS进展至关重要.
研究的目的:
- 调查evolocumab使用与AS进展速度之间的关联.
- 评估埃沃卢库马布对AS中度AS患者AS相关临床事件的影响.
主要方法:
- 追溯观察性研究 (2017-2022年) 包括中度AS患者.
- 在evolocumab使用者和对照组之间比较AS进展标志物 (大动脉速度,压力梯度) 和AS事件.
- 连续回声心脏图用于AS评估,平均随访时间为33个月.
主要成果:
- 与对照组相比,Evolocumab的使用与最大主动脉速度和峰值主动脉压力梯度的每年增加显著缓慢.
- 在evolocumab组 (11%) 和对照组 (58%) 中,AS事件 (死亡,干预,心力衰竭住院) 的累积发生率明显较低.
- 年度进展率和事件发生率的差异的P值在统计学上是显著的 (P<0.05和P=0.012).
结论:
- 埃沃洛库马布的使用表明与缓慢中度大动脉狭窄症的进展有显著的关联.
- 埃沃洛库马布治疗与中度AS患者主要心血管不良事件发生率降低相关.
- 这些发现表明evolocumab在中度AS的管理中可能发挥作用,需要进一步调查.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
176
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
176
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
161
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
161
Anticoagulant Drugs: Low-Molecular-Weight Heparins
692
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
692
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
509
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
509
Ischemic Heart Disease: Overview
1.3K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


